Nivolumab/relatlimab in advanced melanoma: a profile of its use

AbstractNivolumab and relatlimab-rmbw (Opdualag™; hereafter referred to as nivolumab/relatlimab) is a fixed dose combination of monoclonal antibodies for infusion, which expands the number of available therapies against advanced melanoma in patients aged ≥ 12 years. Dual checkpoint inhibition of programmed cell death protein-1 (PD-1) by nivolumab and lymphocyte-activation gene 3 (LAG-3) by relatlimab may stimulate an immune response against tumours. Notably, relatlimab is the first approved treatment targeting LAG-3. Nivolumab/relatlimab significa ntly decreased the risk of disease progression or death in comparison with nivolumab monotherapy during a phase 2/3 trial. The incidence of grade 3 or 4 adverse events was higher with nivolumab/relatlimab than with nivolumab monotherapy; however, no new safety signals were detected during the trial. As with other checkpoint inhibitors, immune-mediated reactions were reported with nivolumab/relatlimab treatment, which may be managed with treatment discontinuation or systemic immunosuppressants.
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research